Overview

  • Product name
    Anti-FGFR1 antibody - ChIP Grade
    See all FGFR1 primary antibodies
  • Description
    Rabbit polyclonal to FGFR1 - ChIP Grade
  • Host species
    Rabbit
  • Specificity
    ab10646 does not react with human FGFR2 and FGFR3.
  • Tested applications
    Suitable for: IHC-P, WB, IP, IHC-Fr, ICC/IF, ChIPmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human FGFR1 aa 360-373 conjugated to Keyhole Limpet Haemocyanin (KLH). Human FGFR1 synthetic peptide with a C-terminally added lysine.
    Sequence:

    EALEERPAVMTSPLK

  • Positive control
    • IHC-Fr: Human fetal cardiac tissue. ICC/IF: HeLa and NIH/3T3 cells. IHC-P: Human umbilical cord tissue.
  • General notes

    Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38 kDa) that are potent physiological regulators of growth and differentiation of a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They also have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of at least 23 members designated FGF1 through FGF23. Four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)]; FGFR2 [bek (bacterial expressed kinase gene product)]; FGFR3 (cek-2), and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported: soluble, secreted, or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed, [e.g. a soluble FGF-binding protein containing the extracellular region of FGFR1 and the secreted form of placental alkaline phosphatase (FRAP1)]. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110- 150 kDa proteins that are constructed of an extracellular ligand binding region with either two (alpha type) or typically three (alpha type) immunoglbulin (Ig)-like domains and an eight amino acid acidic box, a transmembrane region, and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind with a similar affinity several of the FGFs. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGF’s binding to cellular FGFRs depend on or is markedly facilitated by the low-affinity interaction of FGF with the polysaccharide component of the cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR1 is highly expressed in developing human tissues including the brain (preferentially in neurons), vascular basement membranes, skin, and bone growth plates. It may be found in most anchorage dependent cells on their membrane and also may be localized around and in nuclei. Pfeiffer syndrome, as well as other disorders of human skeletal development, is the result of a mutation in the extracellular domain of FGFR1.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage buffer
    pH: 7.40
    Preservative: 0.097% Sodium azide
    Constituents: 0.0268% PBS, 1% BSA
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Purification notes
    The product is an affinity-purified antibody prepared from pooled sera.
  • Primary antibody notes
    Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38 kDa) that are potent physiological regulators of growth and differentiation of a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They also have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of at least 23 members designated FGF1 through FGF23. Four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)]; FGFR2 [bek (bacterial expressed kinase gene product)]; FGFR3 (cek-2), and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported: soluble, secreted, or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed, [e.g. a soluble FGF-binding protein containing the extracellular region of FGFR1 and the secreted form of placental alkaline phosphatase (FRAP1)]. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110- 150 kDa proteins that are constructed of an extracellular ligand binding region with either two (alpha type) or typically three (alpha type) immunoglbulin (Ig)-like domains and an eight amino acid acidic box, a transmembrane region, and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind with a similar affinity several of the FGFs. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGF’s binding to cellular FGFRs depend on or is markedly facilitated by the low-affinity interaction of FGF with the polysaccharide component of the cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR1 is highly expressed in developing human tissues including the brain (preferentially in neurons), vascular basement membranes, skin, and bone growth plates. It may be found in most anchorage dependent cells on their membrane and also may be localized around and in nuclei. Pfeiffer syndrome, as well as other disorders of human skeletal development, is the result of a mutation in the extracellular domain of FGFR1.
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab10646 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/200. Perform enzymatic antigen retrieval before commencing with IHC staining protocol.

The epitopes recognized by the antibody are resistant to routine formalin-fixation and paraffin embedding, and to other fixatives e.g. Methacarn, Bouins solution, ethanol and B5.

WB 1/400. This was determined by blotting using an extract of FGFR-1 transfected cells.
IP Use at an assay dependent concentration.
IHC-Fr 1/300.
ICC/IF 1/200.
ChIP Use at an assay dependent concentration. PubMed: 22514272

Target

  • Function
    Receptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF).
  • Tissue specificity
    Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells.
  • Involvement in disease
    Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
    Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
    Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
    Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
    Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity.
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor.
  • Cellular localization
    Membrane. Nucleus. Cytoplasm. Cytoplasmic vesicle
  • Information by UniProt
  • Database links
  • Alternative names
    • Basic fibroblast growth factor receptor 1 antibody
    • bFGF-R-1 antibody
    • BFGFR antibody
    • CD331 antibody
    • CEK antibody
    • FGFBR antibody
    • FGFR 1 antibody
    • FGFR-1 antibody
    • FGFR1 antibody
    • FGFR1/PLAG1 fusion antibody
    • FGFR1_HUMAN antibody
    • fibroblast growth factor receptor 1 antibody
    • FLG antibody
    • FLT-2 antibody
    • FLT2 antibody
    • Fms-like gene antibody
    • Fms-like tyrosine kinase 2 antibody
    • fms-related tyrosine kinase 2 antibody
    • HBGFR antibody
    • heparin-binding growth factor receptor antibody
    • HH2 antibody
    • HRTFDS antibody
    • hydroxyaryl-protein kinase antibody
    • KAL2 antibody
    • N-SAM antibody
    • OGD antibody
    • Proto-oncogene c-Fgr antibody
    see all

Images

  • ChIP analysis of rat brain lysates, using ab10646 binding FGFR1. Subsequent quantitative PCR analyses of selected potential NBS on the TH gene were performed.

    CX, cortex; CB, cerebellum; VM, ventral midbrain (containing substantia nigra region); OB, olfactory bulb.
  • Immunohistochemical analysis of PFA-fixed frozen human fetal cardiac tissue, labelling FGFR1 with ab10646 at a dilution of 1/300 incubated for 1 hour at 37°C in 10% goat serum, 0.01% Triton & 0.1% saponin in PBS. Permeabilization was done with 0.1% saponin. Blocking was with 10% goat serum incubated at 37°C for 45 minutes. Secondary was a goat anti-rabbit polyclonal Alexa Fluor® 488 conjugate at 1/600.

    See Abreview

  • Immunocytochemical immunofluorescence analysis of methanol fixed HeLa (Human epithelial cell line from cervix adenocarcinoma) cells labelling FGFR1 with ab10646 at a 1/100 dilution. Cells were fixed, then permeabilized. The secondary antibody used was a Goat Anti-Rabbit IgG, Cy3™ conjugate (red). Cells were counterstained with DAPI (blue) to stain nuclei.

  • Immunohistochemical analysis of formalin-fixed paraffin-embedded human umbilical cord sections, labeling FGFR1 with ab10646 at a 5 μg/mL concentration. The secondary used was a biotin-anti-Rabbit IgG Peroxidase.

  • Immunohistochemical analysis of formalin-fixed paraffin-embedded human umbilical cord sections, labeling FGFR1 with ab10646 at a 1/200 dilution.

    Biotinylated secondary followed by avidin-HRP and AEC substrate, hematoxylin counterstain.

    Antigen retrieval: 0.1% trypsin for 15 minutes at 37°C. 

  • Immunofluorescence analysis of NIH/3T3 (Mouse embryo fibroblast cell line) cells, staining FGFR1 using ab10646.

    Top row: Cells were either untreated (left) or treated with FGF2 (50 ng/ml) (right) for 60 minutes.
    Bottom row: Cells were permeabilized with digitonin, and either untreated (left) or treated with FGF2 (50 ng/ml) (right) for 60 minutes.

References

This product has been referenced in:
  • Gai J  et al. Contrast-enhanced computed tomography combined with Chitosan-Fe3O4 nanoparticles targeting fibroblast growth factor receptor and vascular endothelial growth factor receptor in the screening of early esophageal cancer. Exp Ther Med 15:5344-5352 (2018). Read more (PubMed: 29805549) »
  • Santhana Kumar K  et al. TGF-ß Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma. Cell Rep 23:3798-3812.e8 (2018). Read more (PubMed: 29949765) »
See all 33 Publications for this product

Customer reviews and Q&As

1-9 of 9 Abreviews or Q&A

Question
Answer

For diluting these antibodies for western blotting, we recommend PBS, 0.1% Triton X-100, with 1% BSA.

Read More

Answer

Thank you for your enquiry. I am pleased to help answer your questions:

1. I would like to reassure you that both ab108383 and ab6201 are succesfully tested and therefore covered by the Abcam guarantee in ICC-IF. Therefore, any BDNF antibody tested in the species and application you are using should be suitable for your applications. Also, although we produce many in-house antibodies, we obtain other antibodies from a wide range of sources. Therefore, comparison experiments will not often have been done. If you wish to be more certain, I can suggest choosing the antibody that has been best characterized. By this I mean the antibody that has been tested in the most applications and has the most data available (on the datasheet). Also, ensure to select an antibody tested in the species you will be using.

With regards to polyclonal and monoclonal, there is some information on the advantages and disadvantages of both on the following page of our antibody resource guide which I hope will be helpful:

https://www.abcam.com/index.html?pageconfig=resource&rid=11269&pid=11287


2. ICC-IF is immunocytochemistry immunofluoresence, staining of cell cultures on slides. This does not mean it has been tested in flow cystometry. Although it is likely to work in flow cytometry, we cannot guarantee this without further testing. You will need to find an antibody specifically stated as tested in flow cytometry.

FGFR1 antibody [M19B2] (ab823) has been tested in flow cytometry, so this would be the better option for detection of FFFR1 in flow cytometry and ICC-IF, as it would be covered by our guarnatee in these applications.

I am sorry non of our BDNF antibodies has been tested in flow cytometry.All tested applications are specified on our datasheets, and these are updated as soon as any new information is brought to our attention. If you would like to test one of these BDNF antibodies in flow cytometry, please contactme againprior to the purchase by replying to this message as you may be eligible for our testing discount program.

Otherwise, we like to encourage all of our customers to submit an Abreview via the online product datasheet. To find out more about our Abreview system, please see the following link:

https://www.abcam.com/abreviews

3. In answer to your question regarding whether ab823 and ab10646 would be more suitable for your ICC experiments, I would like to reassure you that these are both tested and guaranteed in ICC-IF. The same would apply as for the answer to the same question for BDNF antibodies (answer 1 above).

I hope this information will be helpful to you. If you have any further questions, please do not hesitate to contact us.

Read More

Answer

Thank you for submitting your recent Abreview regarding ab10646. I trust you have received confirmation that your review has been 'published' on Abcam's website. I agree that this vial of ab10646 is not working as expected. If you have received this antibody within 6 months or so of submitting your review, I would be happy to offer you a replacement, credit or refund. In your reply, please let me know the purchase order number or Abcam order reference number associated with this purchase so I can process your request.

Read More
Application
Western blot
Sample
Human Cell lysate - whole cell (U87 (Glioblastoma))
Loading amount
50 µg
Specification
U87 (Glioblastoma)
Treatment
siRNA FGFR1
Gel Running Conditions
Reduced Denaturing (10%)
Blocking step
Milk as blocking agent for 20 minute(s) · Concentration: 10% · Temperature: 20°C

Abcam user community

Verified customer

Submitted Nov 23 2011

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunohistochemistry (Frozen sections)
Sample
Human Tissue sections (human fetal heart)
Permeabilization
Yes - saponin 0.1%
Specification
human fetal heart
Blocking step
Serum as blocking agent for 45 minute(s) · Concentration: 10% · Temperature: 37°C
Fixative
Paraformaldehyde

Abcam user community

Verified customer

Submitted Mar 11 2010

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (Bone Marrow)
Specification
Bone Marrow
Fixative
Paraformaldehyde
Permeabilization
Yes - 1% Triton X-100
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 0.5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted May 05 2008

Answer

Thank you for your enquery. As far as I can see, the originator has only ever tested this material on transfected cells for immunoblotting. However, I have found the originator's immunoprecipitation conditions which I've attached below. I hope this information is helpful. IP Specificity FGFR-1 ~110kD and 120kD major bands RIPA buffer lysates of non-transfected 293T cultured cells and 293T cultured cells transiently transfected with the plasmid pcDNA3/FGFR-1 (flg). - 500ug lysate protein per immunoprecipitation test and 20ul Sepharose Protein A per test. 8% gels, apply immune complex to one or two lanes (10-well combs).

Read More

Answer

Thank you for your enquery. The statement does appear to be contradictory. However, I have spoken to the product manager on this. This statement (taken to together with the suggestion of antigen retrieval), means that antigen retrieval is not absolutely necessary but it is still advisable to do so. Our own QC performed antigen retrieval (via trypsinisation) when assaying this material to ensure a response from the antibody. I hope this information helps. Please do not hesitate to contact us if you need anything further.

Read More

Answer

Thank you for your enquiry. Further to correspondence with the source of this antibody unfortunately I have been unable to determine whether the multiple bands that you have been observing is typical of any of these antibodies. As a general rule if a customer has high background on their blot we recommend that they try changing the blocking buffer to BSA, increasing the stringency and duration of the wash conditions and decreasing the concentration of the antibody. Should you continue to obtain these extraneous bands I would greatly appreciate it if you complete our technical questionnaire by clicking on the links below. This will greatly help our technical team determine the steps that you have taken to optimise this antibody. It would be most useful if you could additionally provide us with the LOT numbers and representative images of the blots. I look forward to hearing from you. ab5481 https://www.abcam.com/index.html?section=western&pageconfig=technical&intAbID=5481&mode=questionaire ab10646 https://www.abcam.com/index.html?section=western&pageconfig=technical&intAbID=10646&mode=questionaire ab10647 https://www.abcam.com/index.html?section=western&pageconfig=technical&intAbID=10647&mode=questionaire ab10649 https://www.abcam.com/index.html?section=western&pageconfig=technical&intAbID=10649&mode=questionaire

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up